Open AccessCitalopram increases the differentiation efficacy of bone marrow mesenchymal stem cells into neuronal-like cells
Author(s) -
Javad Verdi,
Seyed Abdolreza Mortazavi-Tabatabaei,
Shiva Sharif,
Hadi Verdi,
Alireza Shoae-Hassani
Publication year - 2014
Publication title -
neural regeneration research/neural regeneration research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.93
H-Index - 38
eISSN - 1876-7958
pISSN - 1673-5374
DOI - 10.4103/1673-5374.131601
Subject(s) - mesenchymal stem cell , citalopram , bone marrow , stem cell , microbiology and biotechnology , serotonin reuptake inhibitor , population , pharmacology , medicine , biology , cancer research , chemistry , serotonin , immunology , receptor , environmental health
Several studies have demonstrated that selective serotonin reuptake inhibitor antidepressants can promote neuronal cell proliferation and enhance neuroplasticity both in vitro and in vivo. It is hypothesized that citalopram, a selective serotonin reuptake inhibitor, can promote the neuronal differentiation of adult bone marrow mesenchymal stem cells. Citalopram strongly enhanced neuronal characteristics of the cells derived from bone marrow mesenchymal stem cells. The rate of cell death was decreased in citalopram-treated bone marrow mesenchymal stem cells than in control cells in neurobasal medium. In addition, the cumulative population doubling level of the citalopram-treated cells was significantly increased compared to that of control cells. Also BrdU incorporation was elevated in citalopram-treated cells. These findings suggest that citalopram can improve the neuronal-like cell differentiation of bone marrow mesenchymal stem cells by increasing cell proliferation and survival while maintaining their neuronal characteristics.